Human immunodeficiency virus type 1 fitness and tropism: Concept, quantification, and clinical relevance

Clinical Microbiology and Infection

Volumn 16, Issue 10, 2010, Pages 1532-1538

  Clementi, M ^a   Lazzarin, A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antiviral therapy; Fitness; HIV 1; Review; Tropism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS PROTEIN;

ANTIGEN RECOGNITION; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE REPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LOW DRUG DOSE; MONOTHERAPY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; SPECIES DIVERSITY; SPECIES EXTINCTION; TREATMENT PLANNING; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957042910     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03335.x     Document Type: Review

References (36)

1. Eigen M, Biebricher C. Sequence space and quasispecies distribution. RNA genetics 1988, Vol. 3:211-245. Domingo E, Ahlquist PHolland J. eds, Boca Raton, FL, CRC Press
2. Domingo E, Holland J. RNA virus mutation and fitness for survival. Annu Rev Microbiol 1997, 51:151-178.
3. Drake J, Holland J. Mutation rates among RNA viruses. Proc Natl Acad Sci USA 1999, 96:390-393.
4. Domingo E, Holland J, Biebricher C, Eigen M. Quasispecies: the concept and the word. Molecular basis of virus evolution 1995, 171-180. Gibbs A, Calisher C, Garcia-Arenal F, eds, Cambridge, Cambridge University Press
5. Lazaro E, Escarmis C, Perez-Mercader J. Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci USA 2003, 100:10830-10835.
6. Ruiz-Jarabo C, Arias A, Baranowski E. Memory in viral quasispecies. J Virol 2000, 74:3543-3547.
7. Ruiz-Jarabo C, Arias A, Molina-Paris C. Duration and fitness dependence of quasispecies memory. J Mol Biol 2002, 315:285-296.
8. Crandall K. The evolution of HIV 1999, Baltimore, MD, The Johns Hopkins University Press
9. Briones C, Domingo E, Molina-Paris C. Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus. J Mol Biol 2003, 331:213-229.
10. Bagnarelli P, Vecchi M, Burighel M. Genotypic and phenotypic correlates of the HIV-1 env gene evolution in infected children with discordant response to antiretroviral regimens. AIDS Res Hum Retroviruses 2004, 12:1308-1315.
11. Gerry N, Witowski N, Day J. Universal DNA microarray method for multiplex detection of low abundance point mutations. J Mol Biol 1999, 292:251-262.
12. Namikawa R, Kaneshima H, Lieberman M. Infection of the SCID-hu mouse by HIV-1. Science 1998, 242:1684-1686.
13. Menzo S, Monachetti A, Balotta C. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS 2003, 17:663-671.
14. Quinones-Mateu M, Arts E. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat 2002, 5:224-233.
15. Nijhuis M, Deeks S, Boucher C. Implications of anti-retroviral resistance on viral fitness. Curr Opin Infect Dis 2001, 14:29-37.
16. Deeks S, Wrin T, Liegler T. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-478.
17. Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol 2000, 49:41-66.
18. Boeri E, Gianotti N, Canducci F. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. AIDS Res Hum Retroviruses 2003, 19:1151-1153.
19. Canducci F, Sampaolo M, Marinozzi MC. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009, 20:455-460.
20. Canducci F, Marinozzi MC, Sampaolo M. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother 2010, 65:425-433.
21. Weber J, Chakraborty B, Weberova J. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 2005, 43:1395-1400.
22. Diallo K, Marchand B, Wei X. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J Virol 2003, 77:8621-8632.
23. Castagna A, Danise A, Menzo S. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006, 20:795-803.
24. Gianotti N, Tiberi S, Menzo S. HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. J Med Virol 2008, 80:201-208.
25. Nozza S, Galli L, Visco F. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 2010, 27:924-928.
26. Soria A, Danise A, Galli L. Viro-immunological dynamics in HIV1 infected subjects receiving once-daily emtricitabine to delay treatment change after failure: a pilot study. J Clin Virol 2010, 47:253-257.
27. Paredes R, Sagar M, Marconi VC. In vivo fitness cost of the M184V mutation in multidrug resistant HIV in absence of lamivudine. J Virol 2009, 83:2038-2043.
28. Campbell TB, Shulman NS, Johnson SC. Antiviral activity of lamivudine in salvage therapy for multidrug resistant HIV 1 infection. Clin Infect Dis 2005, 41:236-242.
29. Burioni R, Perotti M, Mancini N, Clementi M. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J Hepatol 2008, 49:299-300.
30. Dhillon AK, Donners H, Pantophlet R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007, 81:6548-6562.
31. Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA 2002, 99:13374-13376.
32. Harris KS, Brabant W, Styrchak S. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res 2005, 67:1-9.
33. Zhang H, Yang B, Pomerantz RJ. The cydine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98.
34. Tsibris AMN, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med 2007, 58:13.1-13.15.
35. Svicher V, D'Arrigo R, Alteri C. Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol 2010, 33:195-206.
36. Clementi M. Perspectives and opportunities for novel antiviral treatments targeting virus fitness. Clin Microbiol Infect 2008, 14:629-631.